| Name | Cathepsin Inhibitor 1 |
| Description | Cathepsin Inhibitor 1 is an inhibitor of Cathepsin (L, L2, S, K, B) with pIC50 of 7.9, 6.7, 6.0, 5.5 and 5.2, respectively. |
| In vivo | Ciproxifan intravenously injected at dose of 1 mg/kg decreases the H3-receptor ligand concentration in serum in Male Swiss mice, with half-times of distribution phase of 13min and elimination phase of 87 min, respectively. Ciproxifan (1 mg/kg, p.o.) rises brain t-MeHA level rapidly in Male Swiss mice, being already significantly increased after 30 min, reaching a plateau between 90 and 180 min and still remaining enhanced after 270 min. Ciproxifan leads to ED50 values of 0.23 mg/kg in cerebral cortex, 0.28 mg/kg in striatum and 0.30 mg/kg in hypothalamus in Male Wistar rats. Ciproxifan (3 mg/kg, i.p.) significantly increases choice accuracy as evaluated in the five-choice task performed using a short stimulus duration. Ciproxifan (0.15-2 mg/kg, p.o.) induces marked signs of neocortical electroencephalogram activation manifested by enhanced fast-rhythms density and an almost total waking state in cats. [1] Ciproxifan (10 mg/kg i.p.) enhances prepulse inhibition in the DBA/2 strain mice. [3] Ciproxifan (3 mg/kg i.p.) alleviates hyperactivity and cognitive deficits in the APP Tg2576 mouse model of Alzheimer's disease. [4] Ciproxifan (3 mg/kg i.p.) improves accuracy and decreased impulsivity in adult male hooded Lister rats. [5] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 74 mg/mL (184.13 mM), Sonication is recommended.
Ethanol : 47 mg/mL (116.95 mM), Sonication is recommended.
H2O : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | Inhibitor | inhibit | CysteineProtease | Cysteine Protease | CatS | CatL2 | CatL | CatK | Cathepsin S | Cathepsin L2 | Cathepsin L | Cathepsin K | Cathepsin inhibitor-1 | Cathepsin inhibitor1 | Cathepsin Inhibitor 1 | Cathepsin | CatB |
| Inhibitors Related | Papain | 2-Aminoethanethiol | (S)-(+)-Ibuprofen | Asperphenamate | PMSF | JNJ-10311795 | N-Ethylmaleimide | Z-Lys-OH | Esomeprazole | 2-Cyanopyrimidine | Aloxistatin | 4-Methylesculetin |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Protease Inhibitor Library | Multi-Target Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Covalent Inhibitor Library |
United States
